UBA5 and pancreatic neoplasm: While another independent study showed that the covalent ligand DKM 2-93 can specifically binds the catalytic cysteine residue (Cys250) of UBA5, thereby inhibiting UFMylation and significantly reducing pancreatic cancer cell viability in vitro and in vivo [50].